GSK PLC
GSKHealthcare|Drug Manufacturers - General|UK
$52.78
+0.31 (+0.59%)
DCF (FCF)
$40.01
Earnings Power
$32.61
About
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Stock Price
+33.4%(1Y)
Pipeline Summary
131 total trials47
Phase 1
33
Phase 2
28
Phase 3
28
Phase 4
Completed: 110Terminated: 9SUSPENDED: 1Unknown: 4Active: 4Recruiting: 1NO_LONGER_AVAILABLE: 1Withdrawn: 1
Active Trials (5)
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms
Phase 1Active
Enrollment: 276 participants
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
NCT06065462Ovarian Clear Cell Carcinoma
Phase 1Phase 2Recruiting
Enrollment: 21 participants
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
NCT03833479Cervical Cancer
Phase 2Active
Enrollment: 134 participants
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough
Phase 3Active
Enrollment: 975 participants
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05599191Cough
Phase 3Active
Enrollment: 825 participants
BioScore
5.8/10
Watchlist
Ownership
Recent News
2026-07-10 11:58:41
2026-07-10 11:27:39
2026-07-02 21:50:03
2026-06-24 14:28:55
2026-06-17 21:00:08
Data last updated: Jul 12, 2026, 07:24 PM